Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Adenosarcoma of the uterus 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × RAD1901 × Sarcoma × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡